These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38160620)

  • 1. Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses.
    He Y; Zhou J; Gao H; Liu C; Zhan P; Liu X
    Eur J Med Chem; 2024 Feb; 265():116069. PubMed ID: 38160620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicinal chemistry strategies toward host targeting antiviral agents.
    Ji X; Li Z
    Med Res Rev; 2020 Sep; 40(5):1519-1557. PubMed ID: 32060956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses.
    Zheng Y; Li S; Song K; Ye J; Li W; Zhong Y; Feng Z; Liang S; Cai Z; Xu K
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad-spectrum Respiratory Virus Entry Inhibitors.
    Zhao H; Yuen KY
    Adv Exp Med Biol; 2022; 1366():137-153. PubMed ID: 35412139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of antivirals: broad-spectrum inhibitors.
    Debing Y; Neyts J; Delang L
    Curr Opin Infect Dis; 2015 Dec; 28(6):596-602. PubMed ID: 26524332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pharmacological strategies to fight enveloped viruses.
    Wisskirchen K; Lucifora J; Michler T; Protzer U
    Trends Pharmacol Sci; 2014 Sep; 35(9):470-8. PubMed ID: 25108320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current progress in antiviral strategies.
    Lou Z; Sun Y; Rao Z
    Trends Pharmacol Sci; 2014 Feb; 35(2):86-102. PubMed ID: 24439476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical discovery and development of maraviroc for the treatment of HIV.
    Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
    Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad-spectrum antivirals against viral fusion.
    Vigant F; Santos NC; Lee B
    Nat Rev Microbiol; 2015 Jul; 13(7):426-37. PubMed ID: 26075364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis.
    Prochnow H; Rox K; Birudukota NVS; Weichert L; Hotop SK; Klahn P; Mohr K; Franz S; Banda DH; Blockus S; Schreiber J; Haid S; Oeyen M; Martinez JP; Süssmuth RD; Wink J; Meyerhans A; Goffinet C; Messerle M; Schulz TF; Kröger A; Schols D; Pietschmann T; Brönstrup M
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31666384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomolecular Condensates as Novel Antiviral Targets.
    Martin EW; Iserman C; Olety B; Mitrea DM; Klein IA
    J Mol Biol; 2024 Feb; 436(4):168380. PubMed ID: 38061626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses.
    Lu S; Pan X; Chen D; Xie X; Wu Y; Shang W; Jiang X; Sun Y; Fan S; He J
    Bioorg Chem; 2021 Feb; 107():104619. PubMed ID: 33450541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intervention strategies for emerging viruses: use of antivirals.
    Debing Y; Jochmans D; Neyts J
    Curr Opin Virol; 2013 Apr; 3(2):217-24. PubMed ID: 23562753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral activity of cationic amphiphilic drugs.
    Salata C; Calistri A; Parolin C; Baritussio A; Palù G
    Expert Rev Anti Infect Ther; 2017 May; 15(5):483-492. PubMed ID: 28286997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antivirals with common targets against highly pathogenic viruses.
    Lu L; Su S; Yang H; Jiang S
    Cell; 2021 Mar; 184(6):1604-1620. PubMed ID: 33740455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the potential of repurposing ion channel inhibitors to treat emerging viral diseases and the role of this host factor in virus replication.
    Russell T; Gangotia D; Barry G
    Biomed Pharmacother; 2022 Dec; 156():113850. PubMed ID: 36411658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinase Inhibitors as Underexplored Antiviral Agents.
    García-Cárceles J; Caballero E; Gil C; Martínez A
    J Med Chem; 2022 Jan; 65(2):935-954. PubMed ID: 33970631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting viral entry as a strategy for broad-spectrum antivirals.
    Mazzon M; Marsh M
    F1000Res; 2019; 8():. PubMed ID: 31559009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the development of entry inhibitors for sialic-acid-targeting viruses.
    Heida R; Bhide YC; Gasbarri M; Kocabiyik Ö; Stellacci F; Huckriede ALW; Hinrichs WLJ; Frijlink HW
    Drug Discov Today; 2021 Jan; 26(1):122-137. PubMed ID: 33099021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.